On the one hand, hyperinsulinemia, which is a hallmark of IR, may contribute to the development of cancer because of the oncogenic potential of insulin by increasing the bioactivity of insulin-like growth factor I (IGF-I), enhancing growth factor-dependent cell proliferation, and/or directly affecting cell metabolism (29, 30). The gene discussed is INS; the disease is hyperinsulinism.